AU2022361380A1 - Combination therapies of kras g12d inhibitors with sos1 inhibitors - Google Patents
Combination therapies of kras g12d inhibitors with sos1 inhibitors Download PDFInfo
- Publication number
- AU2022361380A1 AU2022361380A1 AU2022361380A AU2022361380A AU2022361380A1 AU 2022361380 A1 AU2022361380 A1 AU 2022361380A1 AU 2022361380 A AU2022361380 A AU 2022361380A AU 2022361380 A AU2022361380 A AU 2022361380A AU 2022361380 A1 AU2022361380 A1 AU 2022361380A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitor
- kras
- alkyl
- pharmaceutically acceptable
- sos1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252569P | 2021-10-05 | 2021-10-05 | |
| US63/252,569 | 2021-10-05 | ||
| PCT/US2022/045622 WO2023059597A1 (en) | 2021-10-05 | 2022-10-04 | Combination therapies of kras g12d inhibitors with sos1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022361380A1 true AU2022361380A1 (en) | 2024-04-11 |
Family
ID=85803684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022361380A Pending AU2022361380A1 (en) | 2021-10-05 | 2022-10-04 | Combination therapies of kras g12d inhibitors with sos1 inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000863A1 (https=) |
| EP (1) | EP4412718A4 (https=) |
| JP (1) | JP2024537140A (https=) |
| KR (1) | KR20240089358A (https=) |
| CN (1) | CN118382459A (https=) |
| AU (1) | AU2022361380A1 (https=) |
| CA (1) | CA3233570A1 (https=) |
| IL (1) | IL311859A (https=) |
| MX (1) | MX2024004215A (https=) |
| WO (1) | WO2023059597A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| JP2025523101A (ja) * | 2022-07-12 | 2025-07-17 | メッドシャイン ディスカバリー インコーポレイテッド | ピペラジン架橋置換複素環ピリミジン系化合物 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025090811A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Methods of modulating cell proliferation |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217008A1 (en) | 2024-04-08 | 2025-10-16 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| EP4225383A4 (en) * | 2020-10-08 | 2024-12-11 | Kumquat Biosciences Inc. | MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES |
| WO2022217053A1 (en) * | 2021-04-09 | 2022-10-13 | Revolution Medicines, Inc. | Use of sos1 inhibitors with ras inhibitors to treat cancers |
| TW202317589A (zh) * | 2021-07-14 | 2023-05-01 | 美商尼坎醫療公司 | 作為ｋｒａｓ抑制劑的伸烷基衍生物 |
| WO2025085766A1 (en) | 2023-10-20 | 2025-04-24 | Mirati Therapeutics, Inc. | Crystalline forms of fumarate salt of mrtx0902 |
-
2022
- 2022-10-04 AU AU2022361380A patent/AU2022361380A1/en active Pending
- 2022-10-04 CN CN202280077623.1A patent/CN118382459A/zh active Pending
- 2022-10-04 US US18/694,917 patent/US20250000863A1/en active Pending
- 2022-10-04 EP EP22879175.2A patent/EP4412718A4/en active Pending
- 2022-10-04 WO PCT/US2022/045622 patent/WO2023059597A1/en not_active Ceased
- 2022-10-04 KR KR1020247014994A patent/KR20240089358A/ko active Pending
- 2022-10-04 IL IL311859A patent/IL311859A/en unknown
- 2022-10-04 JP JP2024520708A patent/JP2024537140A/ja active Pending
- 2022-10-04 CA CA3233570A patent/CA3233570A1/en active Pending
- 2022-10-04 MX MX2024004215A patent/MX2024004215A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118382459A (zh) | 2024-07-23 |
| WO2023059597A1 (en) | 2023-04-13 |
| IL311859A (en) | 2024-06-01 |
| EP4412718A1 (en) | 2024-08-14 |
| EP4412718A4 (en) | 2025-08-13 |
| JP2024537140A (ja) | 2024-10-10 |
| MX2024004215A (es) | 2024-06-20 |
| CA3233570A1 (en) | 2023-04-13 |
| US20250000863A1 (en) | 2025-01-02 |
| KR20240089358A (ko) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022361380A1 (en) | Combination therapies of kras g12d inhibitors with sos1 inhibitors | |
| AU2019392683B2 (en) | Combination therapies | |
| EP3849537B1 (en) | Combination therapies | |
| US12208099B2 (en) | Combination therapies | |
| US12527795B2 (en) | Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith | |
| EP3849534A1 (en) | Combination therapies | |
| US20240423984A1 (en) | Combination therapies of kras g12d inhibitors with shp-2 inhibitors | |
| US20250177399A1 (en) | Combination therapies | |
| US20260102401A1 (en) | Combination Therapies | |
| HK40109895A (zh) | Kras g12d抑制剂与sos1抑制剂的组合疗法 | |
| HK40109896A (zh) | Kras g12d抑制剂与shp-2抑制剂的组合疗法 |